172 related articles for article (PubMed ID: 18091749)
1. Blood pressure variability causes spurious identification of hypertension in clinical studies: a computer simulation study.
Turner MJ; van Schalkwyk JM
Am J Hypertens; 2008 Jan; 21(1):85-91. PubMed ID: 18091749
[TBL] [Abstract][Full Text] [Related]
2. Carryover effects after cessation of drug treatment: trophies or dreams?
Lumley T; Rice KM; Psaty BM
Am J Hypertens; 2008 Jan; 21(1):14-6. PubMed ID: 18091738
[TBL] [Abstract][Full Text] [Related]
3. Blood pressure variability: the challenge of variation.
Marshall TP
Am J Hypertens; 2008 Jan; 21(1):3-4. PubMed ID: 18091733
[No Abstract] [Full Text] [Related]
4. Renin-angiotensin system blockade safely reduces blood pressure in patients with minor ischemic stroke during the acute phase.
Nakamura T; Tsutsumi Y; Shimizu Y; Uchiyama S
J Stroke Cerebrovasc Dis; 2010; 19(6):435-40. PubMed ID: 20702114
[TBL] [Abstract][Full Text] [Related]
5. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE).
Papademetriou V; Farsang C; Elmfeldt D; Hofman A; Lithell H; Olofsson B; Skoog I; Trenkwalder P; Zanchetti A;
J Am Coll Cardiol; 2004 Sep; 44(6):1175-80. PubMed ID: 15364316
[TBL] [Abstract][Full Text] [Related]
6. Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial.
Saxby BK; Harrington F; Wesnes KA; McKeith IG; Ford GA
Neurology; 2008 May; 70(19 Pt 2):1858-66. PubMed ID: 18458219
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of antihypertensive effect of angiotensin II receptor blockers in patients with essential hypertension by self-measured home blood pressure--HACARARE 300 study].
Msanobu T;
Nihon Rinsho; 2009 Oct; 67(10):2013-20. PubMed ID: 19860206
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).
Maeda A; Tamura K; Kanaoka T; Ohsawa M; Haku S; Azushima K; Dejima T; Wakui H; Yanagi M; Okano Y; Fujikawa T; Toya Y; Mizushima S; Tochikubo O; Umemura S
Clin Exp Hypertens; 2012; 34(4):249-57. PubMed ID: 22571446
[TBL] [Abstract][Full Text] [Related]
9. [Prevension of hypertension by angiotensin receptor blockers in human--TROPHY study].
Ohya Y; Inoue T
Nihon Rinsho; 2008 Aug; 66(8):1596-600. PubMed ID: 18700563
[TBL] [Abstract][Full Text] [Related]
10. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study.
London G; Schmieder R; Calvo C; Asmar R
Am J Hypertens; 2006 Jan; 19(1):113-21. PubMed ID: 16461202
[TBL] [Abstract][Full Text] [Related]
11. [Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals].
Weisser B; Gerwe M; Braun M; Funken C
Arzneimittelforschung; 2005; 55(9):505-13. PubMed ID: 16229114
[TBL] [Abstract][Full Text] [Related]
12. Candesartan cilexetil effectively reduces blood pressure in hypertensive children.
Franks AM; O'Brien CE; Stowe CD; Wells TG; Gardner SF
Ann Pharmacother; 2008 Oct; 42(10):1388-95. PubMed ID: 18664605
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
[TBL] [Abstract][Full Text] [Related]
14. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
Ogihara T; Fujimoto A; Nakao K; Saruta T;
Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
[TBL] [Abstract][Full Text] [Related]
15. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis.
Knudsen ST; Andersen NH; Poulsen SH; Eiskjaer H; Hansen KW; Helleberg K; Poulsen PL; Mogensen CE
Am J Hypertens; 2008 Feb; 21(2):172-6. PubMed ID: 18188164
[TBL] [Abstract][Full Text] [Related]
16. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients.
Suzuki H; Kanno Y;
Hypertens Res; 2005 Apr; 28(4):307-14. PubMed ID: 16138560
[TBL] [Abstract][Full Text] [Related]
17. A dose-response analysis of candesartan-hydrochlorothiazide combination therapy in patients with hypertension.
Karlson BW; Zetterstrand S; Olofsson B; Elmfeldt D
Blood Press; 2009; 18(3):149-56. PubMed ID: 19462314
[TBL] [Abstract][Full Text] [Related]
18. Is low-risk hypertension fact or fiction? cardiovascular risk profile in the TROPHY study.
Nesbitt SD; Julius S; Leonard D; Egan BM; Grozinski M;
Am J Hypertens; 2005 Jul; 18(7):980-5. PubMed ID: 16053996
[TBL] [Abstract][Full Text] [Related]
19. [Beneficial effects of combination therapy with losartan and low-dose hydrochlorothiazide in the treatment of essential hypertension].
Minami J; Ishimitsu T; Matsuoka H
Nihon Jinzo Gakkai Shi; 2005; 47(8):864-9. PubMed ID: 16408430
[TBL] [Abstract][Full Text] [Related]
20. Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies.
Wei F; Jia XJ; Yu SQ; Gu Y; Wang L; Guo XM; Wang M; Zhu F; Cheng X; Wei YM; Zhou ZH; Fu M; Liao YH;
Heart; 2011 Mar; 97(6):479-84. PubMed ID: 21296780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
